Resource

In the development and manufacture of mRNA vaccines and therapeutics, selecting and using the appropriate quality or grade of mRNA raw materials can help you meet critical process, scale, quality, and regulatory needs. Process optimization and risk assessment are important for the production of high‑quality, high‑yield mRNA consistently at scale while minimizing production time and cost. This webinar addresses key considerations in mRNA synthesis and scale‑up to help you accelerate research and development of mRNA vaccines and therapeutics.

Learning objectives:

Review mRNA vaccine and therapeutic development workflow
Understand the importance of raw material selection for mRNA synthesis
Discuss scale-up of mRNA synthesis for process development and commercialization

Speaker:

Sirat Sikka, MS
Field Applications Scientist
Nucleic Acid Therapeutics
Thermo Fisher Scientific

Sirat Sikka has a Master of Science in Biomanufacturing from North Carolina State University. Her research focused on understanding protein–protein interactions. Her career started as a downstream process development scientist at GlaxoSmithKline Vaccines. The responsibilities included process development and optimization for recombinant protein and nucleic acid vaccines. Sirat joined Thermo Fisher Scientific in 2019 as a Purification Applications Scientist and is currently a Field Applications Scientist guiding customers in nucleic acid therapeutics development.

(*Indicates a mandatory field)

First Name*

Last Name*

Institution*

Email*

City*

Country/Region*

What is your current stage of mRNA production?*

In early stages (research & discovery)

Investigating solutions

Actively establishing

Already performing

Not working in mRNA production

For Research Use or Further Manufacturing. Not for diagnostic use or direct administration into humans or animals.